Robbins Geller Rudman & Dowd LLP Announces Pending Class Action in the Puma Biotechnology, Inc. Litigation
March 28 2018 - 11:00AM
Business Wire
The following statement is being issued by Robbins Geller Rudman
& Dowd LLP regarding the Puma Biotechnology, Inc.
Litigation:
Important Notice from
the United States District Courtfor the Central District of California
This statement is intended to give you notice of a pending
Class Action for alleged securities fraud against Puma
Biotechnology, Inc. (PBYI). If you purchased or otherwise
acquired securities of Puma Biotechnology, Inc. (PBYI) between July
22, 2014 and May 29, 2015, you may be a Class member.
At this time, Class members are not required to take any action
to remain in the Class. If any benefits are eventually obtained for
the Class as a result of this lawsuit, eligible Class members may
be entitled to a payment.
Class members may choose to exclude themselves from the Class.
If you exclude yourself, you will not be entitled to a payment if
any benefits are eventually obtained for the Class. If you do not
exclude yourself, you will be bound by any judgment in this
litigation, whether favorable or unfavorable. To remain a Class
member and eligible for a payment if any benefits are eventually
obtained, you are not required to do anything at this time.
Requests for exclusion forms are available at www.pumabiosecuritieslitigation.com or can be
obtained by calling 866-880-1572. The deadline to exclude yourself
is June 6, 2018.
For a full description of the litigation, including
identification of the plaintiff, defendants, Class Counsel, and the
allegations of securities fraud, as well as related Court
documents, please visit:
www.pumabiosecuritieslitigation.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180328005037/en/
Robbins Geller Rudman & Dowd LLPTed Pintar, 619-231-1058
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puma Biotechnology (NASDAQ:PBYI)
Historical Stock Chart
From Sep 2023 to Sep 2024